Human Chorionic Gonadotropin Market 2024 | Size, Trends and Forecast Till 2032

Human Chorionic Gonadotropin (HCG) Industry

Summary:

• The global human chorionic gonadotropin (HCG) market size reached USD 973.5 Million in 2023.

• The market is expected to reach USD 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032.

• North America leads the market, accounting for the largest human chorionic gonadotropin (HCG) market share.

• Natural source extraction accounts for the majority of the market share in the technology segment due to the preference for biologically derived HCG. 

• Female infertility treatment holds the largest share in the human chorionic gonadotropin (HCG) industry.

• Fertility clinics remain a dominant segment in the market.

• The rise in infertility among the masses is a primary driver of the human chorionic gonadotropin (HCG) market.

• The increasing prevalence of cancers, particularly testicular cancer and certain types of ovarian cancer is reshaping the human chorionic gonadotropin (HCG) market.

Industry Trends and Drivers:

• Increasing Infertility Rates:

The rise in infertility rates worldwide is impelling the growth of the market. Infertility affects innumerable couples globally, leading to an increased demand for fertility treatments. Human chorionic gonadotropin (HCG) is widely used in assisted reproductive technologies (ART) like in vitro fertilization (IVF), as it plays a critical role in stimulating ovulation and improving fertility outcomes. Various factors, such as delayed pregnancies, lifestyle changes, environmental factors, and health conditions, are contributing to the growing rates of infertility. Additionally, increased awareness of fertility treatments and the availability of advanced medical technologies are resulting in more people seeking solutions for infertility. With HCG being a crucial hormone in these treatments, the growing prevalence of infertility is driving the demand for HCG.

• Rising Prevalence of Cancer:

The increasing prevalence of cancers, particularly testicular cancer and certain types of ovarian cancer is propelling the market growth. HCG serves as a diagnostic marker for various cancers, aiding in the detection, staging, and monitoring of treatment responses. High levels of HCG are often indicative of the presence of tumors in the reproductive organs, making it a valuable biomarker in oncology. The global rise in cancer cases is leading to a higher demand for diagnostic tools and treatments, contributing to the market growth. In addition, research into the potential role of HCG in cancer therapy is ongoing, which could further expand its use in the future. As cancer rates continue to climb globally, the demand for HCG as both a diagnostic and therapeutic tool is increasing.

• Technological Advancements in HCG Production:

Advances in biotechnology and pharmaceutical manufacturing are also propelling the market growth. The development of more efficient and cost-effective production techniques is leading to increased availability of HCG products. Improved purification methods, recombinant DNA technology, and innovations in drug formulation have enhanced the quality and efficacy of HCG-based medications. This not only boosts product availability but also lowers production costs, making HCG therapies more accessible to patients. Moreover, the growth of personalized medicine and tailored fertility treatments is increasing the need for specialized HCG products that can be customized for individual patient needs. These technological advancements are improving both the supply chain and the effectiveness of HCG treatments for a variety of medical conditions.

Request for a sample copy of this report: https://www.imarcgroup.com/human-chorionic-gonadotropin-market/requestsample

Human Chorionic Gonadotropin (HCG) Market Report Segmentation:

Breakup By Technology:

• Natural Source Extraction

• Recombinant Technology

Natural source extraction represents the largest segment due to the preference for biologically derived HCG, which is considered more effective and safer compared to synthetic alternatives.

Breakup By Therapeutic Area:

• Female Infertility Treatment

• Male Hypogonadism

• Oligospermic Treatment

• Others

Female infertility treatment accounts for the majority of the market share as HCG plays a crucial role in stimulating ovulation and supporting reproductive health in fertility treatments like IVF.

Breakup By End User:

• Fertility Clinics

• Research Institutions

• Others

Fertility clinics represent the leading segment because they are primary providers of reproductive treatments, with HCG being a fundamental hormone used in assisted reproductive technologies.

Breakup By Region:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa 

North America enjoys the leading position owing to its advanced healthcare infrastructure, high awareness of fertility treatments, and significant investments in medical research and biotechnology.

Top Human Chorionic Gonadotropin (HCG) Market Leaders:

The human chorionic gonadotropin (HCG) market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Biocare Medical LLC

• Ferring Pharmaceuticals

• Fresenius SE & Co. KGaA

• Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)

• Lee Biosolutions Inc. (Oy Medix Biochemica Ab)

• Merck & Co. Inc.

• Prospec-Tany Technogene Ltd.

• Scripps Laboratories Inc.

• Sun Pharmaceutical Industries Limited

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163